Soluble Epoxide Hydrolase Inhibitors: Chronic inflammation has long been recognized as a driving force behind many cancers, particularly in conditions such as ulcerative colitis and inflammatory bowel disease. Recent research highlights soluble epoxide hydrolase (sEH) as a key molecular link between unresolved inflammation and carcinogenesis. By degrading epoxyeicosatrienoic acids (EETs)—lipid mediators with strong anti-inflammatory and […]
Author Archives: truemeds
09
Jun
Jun
Tavapadon is a next-generation dopamine D1/D5 receptor partial agonist currently in late-stage development for the treatment of Parkinson’s disease (PD). Clinical trials have shown its effectiveness both as a monotherapy in early PD and as an adjunct to levodopa in advanced stages. Its once-daily oral dosing, targeted receptor profile, and favorable tolerability mark it as […]
09
Jun
Jun
Brensocatib, recently approved by the FDA under the brand name Brinsupri, is the first disease-modifying therapy for non-cystic fibrosis bronchiectasis (NCFB). Unlike traditional symptom-relief treatments, Brensocatib targets the underlying cause of lung inflammation by inhibiting dipeptidyl peptidase 1 (DPP1), reducing neutrophil serine protease activity. Clinical trials (WILLOW and ASPEN) have shown significant improvements in lung […]
Antibody–drug conjugates (ADCs) are redefining cancer therapy by enabling targeted delivery of cytotoxic agents. While traditional ADCs have focused on well-validated targets like HER2 and EGFR, interest is growing in less-explored antigens such as MUC1. MUC1 is overexpressed and aberrantly glycosylated in multiple epithelial cancers, making it a promising yet technically challenging ADC target. This […]
09
Jun
Jun
Enteroviruses, a diverse group of RNA viruses, are increasingly recognized for their ability to cause severe neurological diseases such as encephalitis, meningitis, and acute flaccid paralysis, particularly in children. This blog explores how enteroviruses breach the central nervous system through blood–brain barrier disruption, Trojan horse mechanisms, and retrograde axonal transport. It highlights the role of […]
Uncategorized
Ten Crucial Signaling Pathways in Human Health and Disease: From Cellular Regulation to Drug Targets
09
Jun
Jun
Signaling Pathways in Human Health and Disease: Signaling Pathways are fundamental to cellular communication, regulating vital processes such as growth, immune response, metabolism, differentiation, and apoptosis. This review highlights ten major pathways that have gained significant attention in modern biomedical research and drug development: PI3K/AKT/mTOR, MAPK/ERK, NF-κB, Wnt/β-catenin, JAK/STAT, TGF-β/Smad, Notch, Hippo/YAP, AMPK, and cGAS-STING. […]
09
Jun
Jun
TLR Agonists and Immunotherapy Synergy: Cancer immunotherapy has transformed treatment paradigms, yet a large proportion of patients fail to respond to immune checkpoint inhibitors due to an immunologically “cold” tumor microenvironment. Toll-like receptor (TLR) agonists have emerged as promising agents capable of reprogramming the tumor microenvironment by enhancing antigen presentation, inducing type I interferons, and […]
Abstract: Antibody–drug conjugates (ADCs) represent a promising class of targeted cancer therapies that combine monoclonal antibodies with cytotoxic payloads through specialized linkers. They enable selective tumor cell killing while minimizing damage to healthy tissues. Despite their clinical potential, ADCs face several challenges, including off-target toxicity, limited tumor penetration, and tumor antigen heterogeneity. Recent advances in […]
09
Jun
Jun
MK-0616 is a groundbreaking oral PCSK9 inhibitor developed by Merck, offering a new approach to lowering LDL cholesterol. This innovative macrocyclic peptide therapy shows promise in improving treatment adherence and accessibility for patients with hypercholesterolemia or statin intolerance. While not yet FDA-approved, ongoing trials suggest MK-0616 could become a game-changer in cardiovascular care by combining […]
09
Jun
Jun
Why Everyone’s Targeting PCSK9: PCSK9 has become a prominent target in lipid-lowering drug development due to its key role in regulating cholesterol metabolism. This blog explores its biological mechanism, approved therapeutics, and cutting-edge design strategies, including gene editing, RNA-based therapies, and AI-driven drug discovery. The article also discusses current challenges and future directions for PCSK9-targeted […]